Philips received FDA clearance for use of ultrasound portfolio to manage COVID-19-related lung and cardiac complications
On May 13, 2020, Royal Philips announced that it had received 510(k) clearance from the FDA to market a wide range of its ultrasound solutions for the management of COVID-19-related lung and cardiac complications.
Handheld and portable ultrasound solutions in particular have become valuable tools for clinicians treating COVID-19 patients due to their imaging capabilities, portability and ease of disinfection.
Tags:
Source: Royal Philips
Credit: https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20200612-philips-launches-obstetric-monitoring-solution-to-support-clinicians-and-expectant-mothers-during-covid-19-pandemic.html?src=search
